Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: Renal cell carcinoma (RCC) is highly heterogeneous, with distinct patient management between clear cell RCC (ccRCC) and non-ccRCC groups. Previous bioinformatics and machine learning techniques identified fatty acid binding protein 7 (FABP7) as a potential ccRCC biomarker. However, FABP7 expression studies between ccRCC and non-ccRCC were incomplete. This study aimed to assess FABP7 as a biomarker for distinguishing between ccRCC and non-ccRCC tissue samples.
Patients And Methods: FABP7 expression was evaluated via immunohistochemical staining in 58 RCC cases, including 43 ccRCC and 15 non-ccRCC cases. Staining results were interpreted using H-scores; scores above the cut-off were deemed positive. The correlation between FABP7 expression and clinicopathological RCC features was investigated.
Results: FABP7 positivity was 48.8% in ccRCC and only 13.3% in non-ccRCC cases, with weak positivity in non-ccRCC tissues. FABP7 expression significantly differed between ccRCC and non-ccRCC (p<0.05). This finding was confirmed in a TCGA dataset. However, FABP7 expression was not correlated with other RCC clinicopathological features in our dataset. TCGA results linked FABP7 expression to tumor stage and disease-free survival in patients with ccRCC.
Conclusion: This study preliminarily evaluated FABP7 as a differential diagnostic biomarker in RCC subtyping, showing higher expression in ccRCC than non-ccRCC. FABP7 may serve as a potential diagnostic and prognostic biomarker for ccRCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535899 | PMC |
| http://dx.doi.org/10.21873/invivo.13773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolving trends and clinical-pathological correlations in renal cell carcinoma surgery: a decade-long study at Peking University First Hospital.
Clin Exp Med
August 2025
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, 100034, China.
This study aimed to comprehensively delineate the clinical characteristics, surgical interventions, and evolving trends over the past decade among patients undergoing surgery for renal cell carcinoma (RCC). A retrospective analysis was conducted on the clinical records of 9,110 patients diagnosed with RCC who underwent surgical treatment at Peking University First Hospital between January 2013 and December 2022. Statistical analyses were performed using SPSS 21.
View Article and Find Full Text PDFRenal cancer survival in clear cell renal cancer compared to other types of tumor histology: A population-based cohort study.
PLoS One
July 2025
Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
Introduction: Renal cancer (RC) presents a challenge with increasing incidence and mortality. This study compares RC cancer-specific survival (CSS) and overall survival (OS) based on histological type.
Study Design: This population-based retrospective cohort study covers 1995-2017, utilizing cases from the Finnish Cancer Registry.
Objectives: Adjuvant pembrolizumab has improved overall survival after surgery for clear cell renal cell carcinoma (ccRCC) with an intermediate-high and high risk of recurrence according to the inclusion criteria of Keynote-564 study, but non-RCC mortality is common during postoperative follow-up. We aimed to evaluate the competing risk of death after surgery in patients with ccRCC stratified according to the risk of recurrence with Keynote-564, Three-feature and Leibovich models.
Material And Methods: A total of 1108 patients with ccRCC operated with curative intent between 2005 and 2021 before the use of adjuvant immunotherapy were identified from two academic centres in Finland and Sweden.
Diagnostic performance of the clear cell likelihood score integrated with cystic degeneration or necrosis on MR imaging for identifying clear cell renal cell carcinoma in cT1 solid renal masses.
Insights Imaging
July 2025
Department of Radiology, The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Objectives: To evaluate the diagnostic value of the clear cell likelihood score (ccLS) integrated with cystic degeneration or necrosis on renal MR imaging for diagnosing clear cell renal cell carcinoma (ccRCC) in cT1 solid renal masses (SRMs).
Methods: This retrospective study consecutively enrolled patients with pathologically confirmed SRMs who underwent MRI at the First Medical Center of the Chinese PLA General Hospital between January 2022 and February 2024. Three radiologists independently scored all cT1 SRMs using ccLS and ccLS integrated with cystic degeneration or necrosis (cn-ccLS), with discrepancies reconciled by consensus.
Deep Learning for Detecting and Subtyping Renal Cell Carcinoma on Contrast-Enhanced CT Scans Using 2D Neural Network with Feature Consistency Techniques.
Indian J Radiol Imaging
July 2025
Department of Radiodiagnosis and Interventional Radiology, All India Institute of Medical Sciences, New Delhi, India.
The aim of this study was to explore an innovative approach for developing deep learning (DL) algorithm for renal cell carcinoma (RCC) detection and subtyping on computed tomography (CT): clear cell RCC (ccRCC) versus non-ccRCC using two-dimensional (2D) neural network architecture and feature consistency modules. This retrospective study included baseline CT scans from 196 histopathologically proven RCC patients: 143 ccRCCs and 53 non-ccRCCs. Manual tumor annotations were performed on axial slices of corticomedullary phase images, serving as ground truth.
View Article and Find Full Text PDF